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Paraoxonase 2 overexpression inhibits
tumor development in a mouse model of
ovarian cancer
Asokan Devarajan1, Feng Su2, Victor Grijalva1, Meghna Yalamanchi1, Ashna Yalamanchi1, Feng Gao2,5, Hannah Trost1,
Josephine Nwokedi1, Gina Farias-Eisner3, Robin Farias-Eisner2, Alan M. Fogelman1 and Srinivasa T Reddy1,2,4
Abstract
Ovarian cancer (OC) is most lethal malignancy among all gynecological cancer. Large bodies of evidences suggest that
mitochondrial-derived ROS play a critical role in the development and progression of OC. Paraoxonase 2 (PON2) is a
membrane-associated lactonase with anti-oxidant properties. PON2 deficiency aggravates mitochondrial ROS
formation, systemic inflammation, and atherosclerosis. The role of PON2 in cancer development remains unknown. In
this report, in human, we identified that PON2 expression is higher in early stages (but not in late stages) of OC when
compared to normal tissue. Using a mouse xenograft model of OC, we demonstrate that overexpression of PON2
prevents tumor formation. Mechanistically, PON2 decreases OC cell proliferation by inhibiting insulin like growth
factor-1 (IGF-1) expression and signaling. Intriguingly, PON2 reduces c-Jun-mediated transcriptional activation of IGF-1
gene by decreasing mitochondrial superoxide generation. In addition, PON2 impairs insulin like growth factor-1
receptor (IGF-1R) signaling in OC cells by altering cholesterol homeostasis, which resulted in reduced caveolin-1/IGF-
1R interaction and IGF-1R phosphorylation. Taken together, we report for the first time that PON2 acts as a tumor
suppressor in the early stage of OC by reducing IGF-1 production and its signaling, indicating PON2 activation might
be a fruitful strategy to inhibit early stage ovarian tumor.
Introduction
The precise spatiotemporal control of reactive oxygen
species (ROS) generation is a critical regulator of both cell
survival and death. Mitochondrial oxidative stress and
mitochondrial-derived ROS play an important role in the
vitality of cancer cells and drive signal transduction
pathways, which lead to activation of mitogenic growth
factors, redox sensitive transcription factors, angiogenesis,
and genes involved in cancer cell growth, proliferation,
and survival1–3. Accumulating evidence, from both animal
and human studies, suggests that mitochondrial-derived
ROS4 play a critical role in the development and pro-
gression of OC5.
Paraoxonase 2 (PON2) belongs to the PON gene family,
which consists of PON1, PON2, and PON3. All three
PONs have anti-oxidant properties. PON1 is associated
with HDL whereas, PON2 and PON3 are intracellular
membrane proteins6,7. PON2 is detected in various organs
and all types of cells including vascular cells6,7 and is
localized in the inner mitochondrial membrane, where it
associates with mitochondrial respiratory complex III,
binds Coenzyme Q10, and regulates the respiratory
complex activity and prevents the ubisemiquinone
mediated mitochondrial superoxide levels and oxidative
stress in vascular cells and the liver8. Knockout and
transgenic mouse models have shown that PON2 protects
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against the development of atherosclerosis, obesity, insu-
lin resistance, and neurogenerative diseases6,9–13.
PON2 has been shown to be upregulated in tumor
tissues relative to corresponding normal tissues in many
types of cancers14. However, the role and mechanism
of action of PON2 in cancer has not been elucidated.
In this report, we demonstrate that when injected into
mice, ID8 cells (a mouse ovarian cancer cell line) over-
expressing hPON2 (ID8hPON2) develop significantly
reduced tumor size and volume compared to mice
receiving empty vector-ID8 (ID8EV) cells. Utilizing
molecular, biochemical, and immunological approaches,
we demonstrate that PON2 decreases ovarian cancer cell
proliferation by regulating both IGF-1 expression as well
as IGF-1 signaling. We show that the reduction in IGF-1
levels is c-Jun-dependent and associated with decreased
mitochondrial superoxide levels. Moreover, independent
of IGF-1 levels, PON2 expression alters the IGF-1 sig-
naling by reducing caveolin-1/IGF-1R interaction and
IGF-1R phosphorylation. Our results suggest that PON2
overexpression reduces the tumor forming potential of
ID8 cells by reducing the IGF-1 signaling and its signaling
pathway.
Material and methods
Reagents and cell culture
ID8-cells were transfected with either a pcDNA 3.1
vector carrying a human PON2 cDNA (hPON2) or pcDNA
3.1 vector alone and stable cell lines (ID8hPON2 and ID8EV,
respectively) were established15. ID8hPON2 and ID8EV cells
were routinely cultured in Dulbecco’s Modified Eagles
Medium (DMEM) with high glucose and L-glutamine (2
mM), supplemented with 4% fetal bovine serum (FBS),
penicillin (100 Uml−1), streptomycin (100 μgml−1), 1×
insulin, transferrin, sodium selenite (ITS) liquid media
supplement (Sigma-Aldrich, St. Louis, MO), and G418
(800 μgml−1). The individual experimental treatments for
ID8hPON2 and ID8EV cells were described in detail under
the corresponding figure legends. OVCAR-5 cells were
transiently transfected with either a pcDNA 3.1 vector
carrying a human PON2 cDNA (hPON2) or pcDNA 3.1
vector alone to generate OVCAR-5hPON2 and OVCAR-5EV
cells, respectively that were cultured in RPMI 1640 med-
ium, supplemented with 10% FBS and penicillin (100 U
ml−1), streptomycin (100 μgml−1). Two days post trans-
fection, experiments were performed as described in the
figure legends. We obtained ovarian cancer tissue (Stage I,
Stage II, Stage III, and Stage IV) and normal adjacent tissue
through the Gynecological oncology group and Coopera-
tive human tissue network.
Tissue array studies
The ovarian carcinoma tissue array (#BC11115a and
#OV1004, US Biomax) slides were placed in xylenes to
remove the paraffin, then a series of ethanol. Subsequently
the slide was blocked with 3% H2O2/methanol for 10 min
to inhibit the endogenous peroxidase activity. After a
wash in distilled water, the slide was incubated for 25 min
with EDTA buffer pH 8.00 at 95 °C using Decloaking
Chamber NxGen (Biocare Medical, DC2012). Tissue
section was incubated with rabbit PON2 antibody
(#GTX104061, GeneTex) at the dilution of 1:100 at 4 °C
for overnight. After washing with PBS containing 0.1%
Tween 20, the section was stained with Dako EnVision
System-HRP Labelled Polymer Anti-Rabbit (Dako,
K4003) at room temperature for 30 min. Immunostaining
was visualized using 3,3′-diaminobenzidine (DAB). Sub-
sequently the slide was washed with tap water, counter-
stained with Harris’ Hematoxylin, dehydrated in ethanol,
and mounted with media. Slide was digitized on a Scan-
Scope AT (Leica Biosystems, Inc., Vista, CA) and mor-
phometric analysis performed with Definiens’ Tissue
Studio (Definiens Inc., Parsippany, NJ) to determine the
percentage of PON2-positive cells in a non-biased
method. Briefly, a stain-specific algorithm was created
using the pre-defined cellular detection module and
classification tool, positive and negative stained cells
within a core were identified. Thresholds were set to
classify hematoxylin stain for nuclei and DAB stain for
positive cellular staining. The data were exported to Excel
for further statistical analysis.
Microarray studies
GeneChip Mouse Genome 430 2.0 Arrays (Affymetrix,
Santa Clara, CA) were used to profile the transcriptomes
in ID8hPON2 and ID8EV cell lines. Briefly, biotinylated
complementary RNA (cRNA) was prepared from 100 ng
total RNA. Following fragmentation, 10 μg of cRNA was
hybridized for 16 h at 45 °C on the microarray. GeneChips
were washed and stained in the Affymetrix Fluidics Sta-
tion 450 and then scanned using the GeneChip Scanner
3000 7 G. Quality control and a gene level robust multi-
array average normalization were performed with the
Affymetrix Expression Console software (version 1.3)
Western blot analysis
Cell lysates were collected in lysis buffer containing 0.1
M NaCl, 5 mM EDTA, 50 μM sodium orthovanadate, 1%
Triton X-100, and protease inhibitor tablet (Roche Diag-
nostics, Indianapolis, IN) in 50mM Tris buffer, pH 7.5.
Tissue was homogenized with lysis buffer, centrifuged,
and supernatant was taken for experiments. Fifty micro-
grams of total protein per sample (except for ERK studies
where we used 100 μg) were resolved on 4–15% SDS-
PAGE gels, transferred onto nitrocellulose membranes for
1 h, and blocked in TBS containing 3% milk protein for 1
h. hPON2 was detected using goat hPON2 antibody
(#AF4344, R&D Systems) at 1:500 dilutions. Rabbit IGF-
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1R beta (#9750), phospho-IGF-1R beta (#3918), and rabbit
cyclin D1 (#2978) antibodies (Cell Signaling Technology)
were also used at 1:500 dilution. Actin (#A2228) and
Vinculin (#V9131) antibodies (Sigma Aldrich) were used
at 1:5000 dilution. Primary antibodies were diluted and
incubated in TBS containing 5% milk protein at 4 °C
overnight. The membranes were washed, incubated with
their respective secondary antibodies (1:5000) for 1 h, and
proteins were illuminated using an ECL Plus Western
blotting kit (GE Healthcare, UK).
Subcellular localization studies
To examine whether hPON2 is localized in the mito-
chondria and ER of ID8hPON2 cells, cells were grown in
cover glass with 12 well plates. To detect the mitochon-
dria, cells were treated with Mito Tracker® Red (# M7512,
Thermo Fisher Scientific) for 1 h. After fixation and per-
meabilization, cells were blocked with 1% goat serum
albumin for 1 h at RT and then stained with mouse PON2
antibody (# ab85340, Abcam) for 1 h. Following three
washes with phosphate buffer saline with 0.1% Triton,
cells were incubated with anti-rabbit IgG FITC (1:50
dilution) for 1 h in the dark. To detect the hPON2 in ER,
the experiment was performed as described before.
Instead of Mito Tracker® Red, mouse calnexin antibody
(# sc-23954, Santa Cruz Biotechnology Inc.) and anti-
mouse Rhodamine antibody were used for ER marker.
Images were captured with a fluorescence microscope
(Olympus IX70). Subcellular organelles were isolated
from ID8hPON2 cells as described previously and hPON2
was detected with western blotting (#AF4344, R&D Sys-
tems) as described earlier.
Mitochondrial respiratory complex II+III activity
In total, 100 μg mitochondrial protein from ID8EV and
ID8hpon2 was added with final a concentration of 20 μM
succinate as substrates, 50 μM cytochrome c3+, and 250
μM of potassium cyanide, and the enzymatic activity was
determined at 550 nm (ɛ= 18.5 mM−1 cm−1 ) and activity
was expressed as nanomole cytochrome c reduced per
minute per milligram protein.
Citrate lyase activity
In total, 100 μg cytosolic protein from ID8EV and ID8hpon2
was added with 100mM triethanolamine buffer, 30mM
zinc chloride, 10mM NADH, and 0.50mM sodium citrate
as substrate and enzyme activity was monitored at 340 nM
and activity was expressed nanomole of oxaloacetate
formed per minute per milligram protein.
SiRNA silencing
HeLa, SKOV3, and A549 cultures at about 70% con-
fluence were transfected with either 25 nM of control
siRNA (AllStars Negative Control siRNA, Qiagen), or a
pooled mixture (25 nM each) of the two PON2-specific
siRNA (Hs_PON2_2 HP siRNA, Hs_PON2_6 HP, Qia-
gen). Transfection was performed using the Lipofecta-
mine 2000 kit from Invitrogen according to the
manufacturer’s recommended protocol. Cells were used
in experiments 2 days after siRNA transfection.
Cell proliferation assay using spectrophotometry
Cell proliferation was determined using pyrimidine
analog, 5-bromo-2′-deoxyuridine (BrdU) as described in
manufacturer’s protocol (Roche Applied Science, IN).
Briefly, ID8EV and ID8hPON2 cells were cultured in 96-well
plates and treated as described under figure legends. BrdU
(10 μM) was added to the cells for 2 h; cells were fixed and
incubated with an anti-BrdU antibody-conjugated per-
oxidase for 2 h at 37 °C. Following antibody incubation,
tetramethyl-benzidine substrate solution was added, the
reaction was stopped at the appropriate time by adding
50 μl of 0.5M sulfuric acid, and the absorbance value was
detected at 450 nm using a plate reader (BMG Labtech,
CA). All experiments were performed in triplicates; and
data were expressed as the mean of the triplicate. Cell
proliferation assays were also performed using a FITC
BrdU flow kit (BD-Bioscience, San Jose, USA) according
to manufacturer’s protocol.
Cell proliferation assay and hPON2 detection using flow
cytometer
Following hPON2 siRNA transfection with SKOV3,
HeLa, and A549 cells, cell proliferation was assessed
using FITC BrdU flow kit (#51-2354AK, BD Pharmin-
gen). Briefly, BrdU pulsed cells (1 × 106 cells) were
resuspended in cytofix/cytoperm buffer at room tem-
perature for 30 min. Following washes, cells were
resuspended with cyto-permeabilization plus buffer for
10 min on ice and then refixed for 5 min. Following
washing with buffer, the cells were treated with DNAase
for 1 h at 37 °C. After adding fluorescent antibodies,
Brdu-positive cells were quantified using flow cytometer.
For hPON2 detection, cells were resuspended in cytofix/
cytoperm buffer at room temperature for 30 min. Fol-
lowing washes, cells were resuspended with cyto-
permeabilization plus buffer for 10 min on ice and then
refixed for 5 min. Following washing with buffer, mouse
PON2 antibody at 1:100 (#ab85340, Abcam) was incu-
bated for 1 h subsequently FITC conjugated secondary
antibody was incubated for 30 min and cells were
quantified using flow cytometer.
Cell viability assay
Cell viability assay was measured by MTS method
(#ab197010, Abcam) as described in the manufacture
protocol. ID8EV and ID8hPON2 cells were seeded in 96-
well plates at a density of 2 × 103 per well and mixed with
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20 μl of MTS dye, and then incubated for 30min in the
dark. The optical density (OD) values were measured at
490 nm using BMG labtech plate reader.
Quantitative real-time PCR analysis (qRT-PCR)
ID8EV and ID8hPON2 cells were cultured in six-well
plates and treated as described under figure legends. Total
RNA was extracted from ID8hPON2 and ID8EV cells using
Qiagen RNA isolation kit. The quality and quantity of
RNA were analyzed on a NanoDrop system. cDNA was
synthesized from a high capacity cDNA Reverse Tran-
scription Kit according to the manufacturer’s protocol
(Applied Biosystems, Foster City, CA). Two microliters of
the cDNA was used for the PCR reaction with gene-
specific primers and Q SYBR Green Supermix (BIO-RAD,
Hercules, CA, USA) or green Supermix with Rox (VWR,
Chicago, IL, USA) in a MyiQ Single-Color Real-Time PCR
Detection System (BIO-RAD, Hercules, CA, USA). The
cycling conditions were as follows: 3 min at 95 °C followed
by 40 cycles of: 95 °C, 30 s; 60 °C, 1 min; 72 °C, 1 min;
followed by a final extension at 72 °C for 10 min. The
primer pairs were as follows: (1) mIGF1 (forward),
GTCTTCACATCTCTTCTACCT and (reverse)
AGCAACACTCATCCACAAT, (2) mCyclophilin (for-
ward) GGCCGATGACGAGCCC and (reverse)
TGTCTTTGGAACTTTGTCTGCAA, (3) hIGF-1 (for-
ward) TGGATGCTCTTCAGTTCGTG and (reverse)
TGGTAGATGGGGGCTGATAC, and (4) Beta actin
(forward) GCATCCATGAAACTACATT and (reverse)
CACTTGCGGTGCACGATGG.
Intracellular ROS and mitochondrial ROS measurement
Total ROS was quantified using a 2′,7′-dichloro-
fluorescein (DCF) assay as previously described16,17. IDEV
and ID8hPON2 cells were plated and treated as described in
the Materials and methods sections. Following serum
starvation, cells were incubated with 100 µM DCF (Invi-
trogen, Carlsbad, CA) for 1 h at 37 °C. Cells were washed
with Krebs-Ringer buffer. Fluorescence was measured by
a fluorescence microplate reader (Spectra Max Gemini
XS, Molecular Devices, Sunnyvale, CA) with an excitation
filter at 485 nm and an emission filter at 530 nm. Mito-
chondrial superoxide levels were detected as described8.
Immunoprecipitation
Briefly, 500 μg of protein lysate from ID8EV, ID8hPON2,
scrambled siRNA-treated, and PON2 siRNA-treated cells
were incubated with Caveolin-1 antibody (# 3267S, Cell
Signaling Technology, Danvers, MA) for overnight at 4 °C.
Subsequently, antigen–antibody complexes were incu-
bated with Protein A agarose beads for 3 h at 4 °C. Fol-
lowing three washes, pellets were resuspended with 3×
SDS sample Buffer. Negative control was performed
without antibody. IGF-1R was detected by western
blotting. Caveolin-1 and IGF-1R were also detected from
total lysate (50 μg protein) as input controls.
Enzyme-linked immunosorbent assay
ID8EV and ID8PON2 cells were grown 2–4 days and each
day serum starved for 12 h. Media was collected and IGF-
1 levels were measured following manufacturer’s protocol
using mouse IGF-1 ELISA Kit (# ab100695, Abcam).
Briefly, loading buffer was used to dilute serum and cell
culture medium 1:4 and 1:2, respectively, followed by
overnight incubation at 4 °C. After washing three times
with washing buffer, 1× biotinylated IGF-1 antibody was
added to each well and incubated for 1 h at RT with gentle
shaking. Following this, wells were washed three times
with washing buffer and 100 μL of 1× HRP-Streptavidin
solution was added. TMB solution (100 μL) was added,
and was incubated for 30min at RT in the dark room.
Color density was measured at 450 nm after adding stop
solution. Plasma IGF-1 levels were quantified as described
above.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assay was
performed as described in the manufacturer’s instruction
manual (Active Motif, Carlsbad, California). Briefly, ID8EV
and ID8hPON2 cells were grown in 15 cm plates. After 24 h
(70–80% confluence), cells were serum starved for 12 h.
Cells were fixed with fixing solution (0.54 ml of 37%
formaldehyde in 20ml medium) at RT for 20min to
cross-link the DNA with bound proteins. After washing,
cells were resuspended in lysis buffer containing protease
inhibitors and sonicated to shear the chromatin.
The chromatin was further immunoprecipitated with
C-Jun (#9165), p53 (#2524) (Cell signaling technology,
Danvers, MA), and rabbit or mouse normal IgG as
a control. Chromatin was harvested after immunopreci-
pitation, and then the cross-links were reversed
and the DNA was purified and precipitated. The resulting
DNA was measured primers (Qiagen, C-Jun binding
site primer cat# GPM10289 (+)01A) and p53 binding
site primer GPM1028976(−)01A)) and used as a template
for the real-time PCR. The DNA enrichment after
ChIP was estimated as the percentage bound-to-input
ratio.
Generation of flank tumors in C57BL/6J mice: Six-
week-old female C57BL/6J (Jackson laboratories) mice
were maintained in a pathogen-free animal facility. All
experiments were done in accordance with institutional
guidelines. The mice were housed in a 12–12 h light–dark
schedule and provided food and water ad libitum.
ID8hPON2 or ID8EV cells (5 × 106/mice) were injected
subcutaneously in the right flank of C57BL/6J (n= 15 per
group). At the end of the 5th week, serum was collected,
mice were sacrificed, and tumors were resected. Tumor
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size and volume were determined by Vernier calipers and
using a formula (1/2 × L ×W2) mm3.
Acetyl CoA measurement
Cytosol and mitochondria were isolated as described
previously18. Acetyl CoA was measured using a kit
according to manufacturer’s protocol (#K317, Biovision).
For normalization, protein content was measured in the
samples prior to perchloric acid treatment.
Cholesterol measurement
Lipids were extracted from cell lysates and conditioned
medium collected from ID8EV, ID8hPON2, OVCAR5EV,
OVCAR5hPON2, scrambled siRNA-treated, and PON2
siRNA-treated ID8 cells. Briefly, cells were homogenized
with methanol, isopropanol, and Triton X100. Since
phenol red is interfered with cholesterol reagent, lipids
were extracted and then cholesterol was measured as
described in the manufacturer’s protocol (# C7510, Pointe
Scientific).
Protein estimation
Protein was measured by Bradford method (Sigma
Aldrich, St. Louis, USA).
Statistical analysis
Data was expressed as mean ± SEM where indicated.
Statistical differences were analyzed using the Student’s t-
test or Anova and p values less than 0.05 were considered
statistically significant.
Results
PON2 protein expression is upregulated in ovarian cancer
PON2 mRNA expression is upregulated in a number
of tumor tissues compared to their corresponding nor-
mal tissues19. However, PON2 protein expression
has not been examined at various stages of tumor
development. In the present study, we analyzed PON2
protein expression by immunohistochemistry using
ovarian cancer tissue arrays containing stage I (n= 23),
stage II (n= 20), stage III (n= 35), stage IV (n= 12),
metastasis (n= 10), and control (n= 20) tissues. Our
results show that PON2 protein expression is sig-
nificantly higher in stage I, stage II, and metastasis tis-
sues (Fig. 1a, b). There was no significant change in
PON2 expression in stage IV tissues when compared to
normal tissue (Fig. 1a, b). Although PON2 expression
was increased in stage III, it did not reach statistical
significance when data from all 35 samples were
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Fig. 1 PON2 protein is induced in early stage ovarian cancer. Immunohistochemistry was performed on ovarian carcinoma tissue array slides (US
Biomax Rockville, MD, USA) using PON2 antibody as described under the Materials and methods section. PON2 protein expression was quantified
using Definiens Tissue Studio Software. Representative photographs of the staining are shown in a, and the quantification of the data is presented in
b. Values are expressed as percentage of PON2-positive staining cells. Total protein lysates from matched normal and ovarian tumor tissues [stage I
(n= 7), stage II (n= 10), stage III (n= 12), and stage IV (n= 15)] were subjected western blotting analyses using hPON2 antibody. Representative
blots (two sets from each stage) are shown in c. The data were quantified using Image J software and presented in d
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averaged and compared to control group (n= 20)
(Fig. 1b). Western blotting data showed that PON2
protein expression (observed as a doublet due to the two
isoforms present in humans20) is significantly higher in
stage I and stage II when compared to adjacent normal
tissue, whereas there was no significant change in stage
III and stage IV (Fig. 1c, d).
Establishment of the stable ID8EV and ID8hPON2 cell lines
To study the role of PON2 in ovarian cancer, ID8-cells
were transfected with either a pcDNA 3.1 vector carrying a
human PON2 cDNA (hPON2) or pcDNA 3.1 vector alone
and stable cell lines (ID8hPON2 and ID8EV, respectively)
were established and stable mouse ovarian cancer cell lines
were generated using G418 as a selective marker. As shown
in Fig. 2a, hPON2 was detected only in ID8hPON2 cells, but
not in ID8EV. Subcellular fractions were isolated and PON2
was detected in mitochondria and post-mitochondrial
pellet (endoplasmic reticulum and microsomal fractions)
by western blotting (Fig. 2b). We further confirmed the
subcellular localization of hPON2 with ID8hPON22 cells
using immunofluorescent studies. As seen in Fig. 2c, d,
hPON2 was localized to mitochondria and ER. Further-
more, functional assays demonstrated that mitochondrial
ETC Complex II+ III activity (Fig. 2e) was significantly
increased along with decreased mitochondrial (Fig. 2f)
superoxide levels in ID8hPON2 compared to that of ID8EV
cells. There was no difference in GRP78 and CHOP
expression between ID8EV and ID8hPON2 cells (data not
shown). While there was no difference in cell viability
between ID8EV and ID8hPON2 cells, cell proliferation was
significantly decreased in ID8hPON2 cells compared to
ID8EV cells (Fig. 2g, h).
Expression of hPON2 reduces ID8 cell capacity to form
tumors in mice
To test whether overexpression of hPON2 modulates
tumor growth, an in vivo experiment was performed as
described in the figure legends. As seen in Fig. 3a–c, when
compared to mice that received ID8EV cells, mice that
received ID8hPON2 cells had significantly (p < 0.01) reduced
tumor weight (ID8EV mice 51 ± 14 mg vs. ID8hPON2 mice
32 ± 14mg) and reduced tumor volume (ID8EV 104 ± 40
mm3 vs. ID8hPON2 41 ± 27mm3).
Fig. 2 Characterization of ID8EV and ID8hPON2 cells. a) Expression of hPON2 protein was analyzed by western blotting in ID8EV and ID8hPON2 stable
cell lines. b) ID8EV and ID8hPON2 cell fractions were subjected to western blotting for PON2 and COX IV proteins. c) Colocalization of mitochondrial
marker and PON2. ID8EV and ID8hPON2 cell were fixed and stained with Mito Tracker® Red (a mitochondrial marker, red) and PON2 antibody (green).
The merged image of hPON2 and mitochondria (yellow) is shown in the bottom panel. d) Colocalization of ER marker and PON2. ID8EV and ID8hPON2
cell were fixed and stained for Calnexin (green), an ER marker, and hPON2 (red). The merged image of hPON2 and Calnexin is shown in the bottom
panel. e) Mitochondria were isolated from ID8EV and ID8hPON2 cells and respiratory complex II+ III assay was carried out as described in Materials and
methods section. The results are expressed as Cytochrome c reduced/min/mg protein. f) mitochondrial superoxide levels were measured as
described in the methods and values were expressed as fold change over the ID8EV. *p < 0.05 compared to IDEV cells. g) ID8EV and ID8hPON2 cells
were cultured for 48 h, serum starved for 12 h, and cell viability was measured as described in the method section. h) 5 × 103 ID8EV and ID8hPON2 cells
were cultured for 48 h, serum starved for 12 h and cell proliferation was assessed using BrdU by spectrophotometry as described in the Materials and
methods section
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hPON2-mediated gene expression and cell proliferation in
an ex vivo model
To determine the mechanism by which overexpression
of hPON2 inhibits tumor size and volume, microarray-
based gene expression profiling was performed on total
RNA isolated from ID8hPON2 and ID8EV cells. Detailed
gene expression changes and associated pathways are
shown in Supplementary Tables 1–3. In ID8hPON2 cells,
the expression profile of many genes known to regulate
tumor growth including BRCA1, cyclin and cyclin-
dependent kinase 20, PTK2, Hypoxia-upregulated pro-
tein 1, p21-activated kinase 3, IL-18, IL-33, IGF-1, IGFBP2
and RNA-binding protein 9, were identified.
PON2 expression reduces IGF-1 expression and inhibits ID-
8 cell proliferation
Among genes listed in Supplementary Tables 1–3, IGF-1,
an inducer of cell proliferation was selected for further
investigation since IGF-1 has previously been implicated in
ovarian cancer21. We first validated IGF-1 gene expression
using qPCR (Fig. 4a). IGF-1 gene expression was sig-
nificantly decreased (~2.25 fold) in ID8hPON2 cells com-
pared to ID8EV cells (Fig. 4a). Furthermore, at protein
levels on day 1 in cell culture supernantant showed trend
towards reduced IGF-1 levels in ID8hPON2 when compared
to ID8EV cells, and by day 2 and day 3, when compared to
ID8EV cells, IGF-1 was significantly decreased in ID8hPON2
cells (Fig. 4b). IGF-1 gene expression in tumor tissues and
plasma IGF-1 level were significantly reduced in mice that
received ID8hPON2 cells when compared to mice that
received ID8EV cells (Supplementary Fig. 1A).
We next examined the effect of endogenous PON2
inhibition on IGF-1 expression in human cancer cell lines
including ovary (SKOV3), cervical (HeLa), and lung
(A549). PON2 gene expression was reduced by more than
50% in all the cell types tested following transfection with
PON2 Si RNA (Fig. 4c). IGF-1 expression was sig-
nificantly increased in SKOV3 cells (Fig. 4d) but not in
HeLa and A549 cells, suggesting that there might be a cell
specific role for PON2 in mitigating IGF-1 expression.
Knockdown of PON2 in ID8 cells (mouse ovarian cancer
cells) also resulted in increased IGF-1 expression like that
observed in SKOV3 cells (data not shown).
We examined whether hPON2 modulates cell pro-
liferation using Brdu incorporation assays. Since FBS
contains various hormones and growth factors including
IGF-1, we optimized conditions for serum starvation (to
synchronize cells) without completely blocking cell pro-
liferation. We determined that 12 h starvation is ideal for
these experiments (Supplementary Fig. 2). As seen in Fig.
4e, there was a trend towards reduced proliferation in
ID8hPON2 cells when compared to ID8EV cells by day 1 in
an ex vivo model. Differences in proliferation between the
ID8EV and ID8hPON2 were significant by day 2 and day 3.
To determine whether the effect on proliferation is cell
autonomous, we obtained conditioned medium (days 1, 2,
and 3) from ID8hPON2 and ID8EV cell cultures as indicated
in figure legend and incubated them with ID8 cells for 24 h
and cell proliferation was measured. Treating ID8 cells
with conditioned medium from ID8hPON2 cells resulted in
reduced proliferation (significant difference on day 2 and 3
but not day 1) when compared to ID8 cells treated with
conditioned medium from ID8EV as seen in Fig. 4f. To
determine whether decreased cell proliferation in ID8hPON2
was due to IGF-1 levels, ID8EV and ID8hPON2 cells were
grown for 2 days and serum starved for 12 h with 500 nM
IGF-1 antibody or without IGF-1 antibody and cell pro-
liferation was assessed. In the presence of IGF-1 antibody,
the proliferation of both ID8EV and ID8hPON2 cells was
inhibited and the level of proliferation was not different
between the two cell types suggesting PON2 inhibits cell
proliferation via IGF-1 levels (Fig. 4g). Additionally, cell
proliferation was assessed with different cell types. Relative
to scrambled siRNA-transfected cells, cell proliferation was
significantly increased in PON2-siRNA transfected SKOV3
cells in contrast to PON2-siRNA transfected HeLa cells
(Fig. 4h). However, there was no change in cell prolifera-
tion between PON2-siRNA and scrambled siRNA trans-
fected A549 cell lines (Fig. 4h).
PON2 reduces the IGF-1 level via C-Jun transcription factor
in ID8 cells
Since C-Jun and P53 transcription factors induce a
number genes implicated in tumor formation, we exam-
ined whether these transcription factors influence IGF-1
levels. ChIP experiments revealed that the recruitment of
C-Jun (but not p53) to the IGF-1 promoter was lowered
(Fig. 5a, b) in ID8hPON2 cells. To further, confirm whether
hPON2 is directly responsible for this effect, hPON2 was
silenced with siRNA in ID8hPON2 cells and were assayed for
hPON2 protein expression, c-Jun recruitment, IGF-1
expression, cell proliferation, and mitochondrial super-
oxide levels. As seen Fig. 5c, d, PON2 expression was sig-
nificantly reduced in siRNA-treated ID8hPON2 compared to
scrambled siRNA-treated ID8hPON2 cells. Furthermore,
upon PON2 siRNA treatment, the difference between
ID8EV and ID8hPON2 cells with respect to C-Jun recruit-
ment (Fig. 5e), IGF-1 (Fig. 5f), cell proliferation (Fig. 5g),
and mitochondrial superoxide (Fig. 5h) levels were sig-
nificantly decreased.
PON2 inhibits cell proliferation via IGF-1 signaling pathway
by altering the caveolin-1– IGF-1R interaction in ID8 cells
To determine whether PON2 inhibits cell proliferation
via IGF-122 alone we performed restoration experiments
as described in the figure legends (Fig. 6a). At 12 h and 24
h, cell proliferation was induced in both ID8EV and
ID8hPON2 cells. However, compared to ID8EV, ID8hPON2
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cells had reduced cell proliferation (Fig. 6a). These results
suggested that at early time points reduction in cell pro-
liferation in ID8hPON2 cells is mediated by factors other
than IGF-1 protein because IGF-1 secretion was
decreased only 72 h after plating these cells. But here,
even 48 h after plating (i.e., 24 h plating, 12 h serum
starvation, 12 h treatment), there was decreased cell pro-
liferation. As a first step, we examined IGF-1 signaling
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pathway as described in the figure legends (Fig. 6b). While
IGF-1R was not altered, phosphorylation of IGF-1R gra-
dually increased. However, compared to ID8EV cells,
phosphorylation of IGF-1R was lower in ID8hPON2 cells
(Fig. 6b). Similarly, although the total level of ERK-1/ERK-
2 was not different, phosphorylation of ERK-1/ERK-2 was
significantly increased upon IGF-1 treatment in both
groups. However, compared to ID8EV cells, phosphor-
ylation of ERK-1/ERK-2 was lower in ID8hPON2 cells.
Same trend was seen for cyclin D (Fig. 6b).
Since deficiency of caveolin-1, a principle component of
caveolae (a special type of lipid raft present in plasma
membrane) decreases the IGF-1 signaling23, we measured
caveolin-1 levels in our experiments. While there was no
difference in caveolin-1 levels and total IGF-1R levels,
caveolin-1–IGF-1R interaction levels were lower as seen
in Fig. 6c. Since cholesterol-depleted cells disturb the
structure of rafts and lead to the release of their protein
components into the adjacent plasma membrane, we
measured both intra- and extracellular (medium) cho-
lesterol levels. In addition, acetyl CoA, a precursor of
cholesterol biosynthesis, was measured in the mitochon-
dria and cytosol. Relative to ID8EV, intracellular (Fig. 6d)
and extracellular (not shown) cholesterol levels were
significantly lower in ID8hPON2 cells. As seen in Fig. 6e,
cytosolic acetyl CoA was significantly lower, whereas
mitochondrial acetyl CoA significantly increased in
ID8hPON2 cells as compared to that of ID8EV. Knockdown
of PON2 in ID8 cells reversed this effect (data not shown).
A cytosolic citrate lyase enzyme converts citrate (derived
from mitochondria) into acetyl CoA, which was sig-
nificantly lower (Fig. 6f) in ID8hPON2 cells as compared to
that of ID8EV cells.
To ascertain that our results are not ID8 cell specific, we
confirmed key results described above in an additional
ovarian cancer cell line OVCAR-5 cells (Supplementary
Results and Supplementary Fig. 3). Figure 7 illustrates the
anti-tumorigenic effects of hPON2 in ovarian cancer.
Discussion
Despite growing evidence suggesting that PON2 ame-
liorates atherosclerosis, Type II diabetes, and neurode-
generative diseases9,13,23, its role in cancer has not been
established in an in vivo model. In this study, using an
ovarian cancer model, we report, for the first time, that:
(1) PON2 is overexpressed in early stages (but not in late
stages) of ovarian cancer and (2) in mice, overexpression
of PON2 reduces ovarian tumor size and volume in a
xenograft model. Our results also demonstrate novel
mechanisms for PON2 involving IGF-1 expression and
signaling and regulation of immune function.
Why PON2 is differentially regulated at various stages of
ovarian cancer and what is its role in ovarian tumor
formation?
It has been reported that PON2 and PON3 are
upregulated in various cancer tissues including ovarian
cancer14,15,19,24–28. Studies suggest that PON1 poly-
morphisms are associated with various cancers including
ovarian cancer and its activity was negatively correlated
with ovarian tumor size in human subjects providing
clinical evidence for a link between PON and cancer29–31.
This is the first report demonstrating a role of PONs in an
in vivo cancer model. This present study suggests that
PON2 is overexpressed in early stages of ovarian cancer in
human subjects (Fig. 1a, b) and its expression is negatively
associated with tumor size and volume (Fig. 3a–c) in a
mouse model. Senthil et al.32 reported that plasma
from ovarian cancer patients shows decreased anti-
oxidant enzyme activities including catalase, extra-
cellular SOD, and non-enzymatic antioxidants such as
vitamin C and E along with increased concentrations of
plasma thiobarbituric acid reactive substances and con-
jugated dienes. Intracellular ROS may induce PON2
expression and our in vivo model further implies that
induction of PON2 as a protective mechanism. Prior
studies suggest that PON2 is upregulated in response to
Fig. 4 PON2 overexpression reduces IGF-1 expression and inhibits cell proliferation in ID8 cells. a) 3 × 105 ID8EV cells or ID8hPON2 cells were
cultured on six-well plates in DMEM medium containing high glucose and L-glutamine (2 mM) and supplemented with 4% fetal bovine serum (FBS),
penicillin (100 Uml−1), streptomycin (100 μgml−1), and 1× ITS liquid media supplement (10 μgml−1 insulin, 5 μgml−1 transferin, and 5 ngml−1
sodium selenite). Cells were incubated at 37 °C for 24 h in 5% CO2 and then starved for 12 h in serum free media. Total RNA was isolated and cDNA
was prepared as described under materials and methods. IGF-1 mRNA was quantified by qPCR and normalized to cyclophilin. b) 3 × 105 ID8EV and
ID8hPON2cells were grown 1–3 days and each day serum starved for 12 h, then cell culture supernatants were collected and IGF-1 protein levels were
quantified by ELISA as described under Materials and methods. hPON2 siRNA or scrambled siRNA was transfected into SKOV3, HeLa, and A549 cells at
70% confluence. PON2 protein expression was quantified after 2 days as described under the Materials and methods (c). Total RNA was isolated and
IGF-1 was quantified by qPCR (d). e) 5 × 103 ID8EV and ID8hPON2 cells were grown as indicated in b and cell proliferation was assessed using Brdu by
spectrophotometry as described in the Materials and methods. f) ID8EV and ID8hPON2 cells were grown and serum starved as in b and each day
conditioned media were collected. Subsequently, the media were incubated with ID8 cells for 48 h, and cell proliferation was assessed as described
in the Materials and methods section. g) ID8EV and ID8hPON2 cells were grown for 2 days and serum starved for 12 h with 500 nM IGF-1 antibody
(# ab9572, Abcam) or without IGF-1 antibody and cell proliferation was assessed as described in the materials and methods section. h) Following
hPON2 siRNA transfection with SKOV3, HeLa, and A549 cells, cell proliferation was assessed using FITC Brdu. Brdu-positive cells were quantified using
flow cytometer. *p < 0.05, compared to ID8EV. Values were expressed as fold (n= 3)
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Fig. 5 PON2 reduces the IGF-1 level via C-Jun transcription factor in ID8 cells. ID8EV and ID8hPON2 cell culture lysates were prepared and utilized
for chromatin immunoprecipitation assays with C-Jun (a) and p53 (b) antibodies. c) Equal number of ID8hPON2 cells were plated in six-well plates. At
60 % confluence level, ID8hPON2 cells were transfected with either hPON2 siRNA or scrambled siRNA, and PON2 expression analyzed by western
blotting. d) Data in c are quantified using ImageJ software. e) Four six-well plates of cells were pooled from PON2-siRNA-treated ID8hPON2 or
scrambled siRNA-treated ID8hPON2 cells. Chromatin immunoprecipitation assay was performed and C-Jun promoter was quantified (e) as described in
the materials and methods section. Cell culture supernatants obtained from cells described under (e) and IGF-1 level was analyzed by ELISA (f), g) cell
proliferation, and h) mitochondrial superoxide levels were measured as described in the method section. *p < 0.05, compared to ID8EV. Values were
expressed as fold changes (n= 3)
Devarajan et al. Cell Death and Disease  (2018) 9:392 Page 11 of 16
Official journal of the Cell Death Differentiation Association
A0
2
4
6
8
10
12
14
16
18
20
6hrs
12 hrs
24 hrs
*
*
IGF-1Veh
Veh IGF-1
Veh IGF-1Ce
ll 
pr
ol
ife
ra
tio
n 
(fo
ld
)
0 min 30 min 60min 90min
p-IGF-1R
IGF-1R  
Cyclin D1 
Vinculin 
p-ERK-1/ERK-2
ERK-1/ERK-2
MW 
(kDa)
110
110
40
40
110
B
40
Caveolin-1 
IGF1-R
Vinculin 
110KDa
40KDa
110KDa
20KDa
110KDa
IGF1-R
Heavy chain
IP
Input
C
ID8EV ID8hpon2
D
ID
8
EV
ID
8
hP
ON
2
ID
8
EV
ID
8
hP
ON
2
ID
8
EV
ID
8
hP
ON
2
ID
8
EV
ID
8
hP
ON
2
ID
8
EV
ID
8
hP
ON
2
ID
8
EV
ID
8
hP
ON
2
ID
8
EV
ID
8
hP
ON
2
ID
8
EV
ID
8
hP
ON
2
ID
8
EV
ID
8
hP
ON
2
ID
8
EV
ID
8
hP
ON
2
0
100
200
300
C
ho
le
st
er
ol
 (µ
g)
/
1X
10
6  c
el
ls *
E
0.0
0.5
1.0
1.5
2.0
A
ce
ty
l-C
oA
 (f
ol
d)
*
*
Cytosol Mitochondria F
0
50
100
150
200
O
xa
lo
ac
et
at
e 
fo
rm
ed
nM
/m
in
/m
g 
pr
ot
ei
n
*
Fig. 6 Overexpression of hPON2 inhibits cell proliferation via IGF-1 signaling pathway by altering the caveolin-1 and IGF-1R interaction in
ID8 cells. a) 5 × 103 cells were plated in 96 well plates and were incubated at 37 °C in 5% CO2. After 24 h, cells were serum starved for 12 h. Following
this, cells were treated with IGF-1 at the concentration of 500 nM or vehicle for 6 h, 12 h, and 24 h. Cell proliferation was measured as described
above. b) ID8EV cells or ID8hPON2 cells were cultured in six-well plates as described above and treated with IGF-1 at the concentration of 1 µM for 30,
60, and 90min. 50 µg of total protein (100 µg for ERK1/2) was subjected to western blotting and phosphorylated IGF-1R, total IGF-1R, phosphorylated
ERK1/2, total ERK1/2, cyclin D1, and vinculin were detected using respective antibodies as described in the materials and methods section. c)
Immunoprecipitation was performed with caveolin-1 antibody and IGF-1R was detected by western blotting. d) Lipids were extracted from ID8EV and
ID8hPON2 cells using chloroform: isopropanol: NP (7:11:0.11), air dried at 50 °C to remove the chloroform and placed under vacuum for 30 min,
dispersed with assay buffer and cholesterol was measured as described in the Materials and methods section. e) Mitochondria and cytosol were
isolated as described in the materials and methods section and acetyl CoA was measured using a kit according to manufacturer’s protocol. Values
were normalized based on protein concentration. Values were expressed as fold change (n= 3). f) Citrate lyase enzyme activity was measured as
described in the Materials and methods section. (n= 3). *p < 0.05, compared to ID8EV
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oxidative stress in both an ex vivo and in vivo model33,34.
Consistent with our study, Yumin et al.35 have reported
that mitochondrial Mn superoxide dismutase (Mn SOD)
(which converts toxic superoxide to the less toxic
hydrogen peroxide) expression was high in ovarian tumor
tissue and its expression was induced by mitochondrial
oxidative stress. Over expression of mitochondrial
Mn-SOD reduced ovarian cancer tumor growth by ame-
liorating mitochondrial superoxide/oxidative stress35.
Balliet et al.36 demonstrated that mitochondrial tran-
scription factors A (TFAM) deficient fibroblasts showed
evidence of mitochondrial oxidative stress, decreased
respiratory complex activity, with the loss of certain
mitochondrial respiratory chain components and sig-
nificantly promoted the tumor growth in a breast cancer
xenograft model. Although currently it is unknown why
PON2 was downregulated in late stages of ovarian cancer
compared to early stages within the ovary and in lymph
node where it was increased. Possibilities include (1)
diverse cell–cell interactions in early vs. late stages that
lead to different PON2 expression and (2) adaptive
mutations in late stage that prevent PON2 expression.
Whatever the cause, based on our in vivo model, we can
conclude that decreased expression of PON2 in late stages
would be associated with cancer progression. Further
work needs to address the role of PON2 in an in vivo
metastatic tumor model.
How does PON2 reduce IGF-1 levels and cell proliferation
in ovarian cancer cell lines?
Perturbation of redox homeostasis alters c-Jun activa-
tion. For example, activated forms of c-Jun and JNK have
been reported in muscle fibers with respiratory chain
deficiency along with increased mitochondrial ROS37.
Further, Li et al. reported that embryonic fibroblasts from
c-Jun knockout mice show decreased secretion of IGF-1
and inhibited benign prostatic hyperplasia-1 prolifera-
tion38. Mice lacking c-Jun in hepatocytes had reduced
IGF-1 expression39. Our ChIP study suggests that
decreased mitochondrial superoxide levels (Fig. 2f) in
ID8hPON2 recruit c-Jun at the promoter of IGF-1 to a
lesser degree (Fig. 5a). The present study demonstrates
that mitochondrial superoxide was significantly decreased
in ID8hPON2 cells, but there was no difference in ER stress
Fig. 7 Schematic presentation of a working model for the role of PON2 in ovarian tumor growth. ID8 cells form tumors in immunocompetent
C57BL6/J mice. ID8hPON2 cells overexpressing human PON2 develop reduced tumors. Based on the data presented in this paper, PON2
overexpression regulates three anti-tumorigenic pathways. I). PON2 overexpression reduces mitochondrial superoxide levels, which regulate c-Jun
activation. Reduced c-JUN binding to the IGF-1 promoter leads to decreased expression of IGF-1 protein. II). PON2 expression enhances electron
transport chain activity leading to decreased cholesterol levels resulting in impaired caveolin-1 and IGF-1R interaction. I & II result in decreased cell
proliferation and reduced tumor growth
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marker genes such as GRP78 and CHOP between ID8EV
and ID8hPON2 suggesting mitochondrial ROS plays an
important role in activating the c-Jun transcription factor,
which further regulates IGF-1 levels.
Using various cancer cell line models, it has been
shown that overexpression of PON2 protects from cell
death by reducing mitochondrial superoxide levels. Based
on this information, Witte et al. speculated that PON2
may promote tumor growth40. It should be noted
that cancer is a multistage process of initiation, progres-
sion, and metastasis. Superoxide/oxidative stress not
only induces apoptosis, it also can stimulate the
epithelial–mesenchymal transition processes where epi-
thelial cells alter various metabolic processes that permit
development of a mesenchymal phenotype, a process
that is responsible for initiation and metastasis41,42. In
addition, it has been shown that ROS/antioxidant
genes modulate tumorigenesis in a spatiotemporal man-
ner. For example, NRF2 a transcription factor (that
induces antioxidant gene expression) inhibits cell
proliferation in U25MG human glioma cells and tumor
growth in a xenograft mouse model43 but it induces
cell proliferation in human hepatocellular carcinoma
lines44. Based on specific requirements and cellular
chemistry, ROS modulates the survival pathway or death
pathway by altering gene expression/activity with different
cell types.
How does PON2 reduce IGF-1 signaling in ovarian cancer
cells?
Receptor and ligand levels cannot solely explain recep-
tor autophosphorylation and its downstream signaling
pathways. For example, in type II diabetes, despite insulin
and insulin receptor-1 (IRS-1) levels being similar to
control subjects, the signaling pathway is impaired45.
Accumulating evidence suggests that membrane fluidity,
clustering of the receptors, and receptors and other pro-
tein interactions that define signaling pathways are
mediated by cellular cholesterol levels46. The precursor of
cholesterol is acetyl CoA which is mainly generated from
fatty acid oxidation and pyruvate decarboxylation pro-
cesses both of which occur in the mitochondria. Since
acetyl CoA cannot enter the cytosol, an intermediate
compound of the tricarboxylic acid (TCA) cycle, “citrate”
exits the mitochondria to enter the cytosol where it reacts
with Co-A to form acetyl-CoA and oxaloacetate by citrate
lyase47. Furthermore, electron transport chain (ETC) and
the TCA cycle are tightly regulated48. For example, ETC
generates the NAD and FAD which act as cofactors in the
TCA cycle48. Thus, decreased cholesterol in ID8hPON2
(Fig. 6d) cells may be due to constantly increased ETC
activity triggering the TCA cycle instead of forming acetyl
CoA from citrate. Indeed, in our study, succinate dehy-
drogenase (the only enzyme involved in TCA cycle ETC)
activity was increased (Fig. 2e) in PON2-overexpressing
cells with decreased acetyl CoA (Fig. 6e) in the cytosol.
Previously, it has been shown that PON2 deficiency in
mice increases the serum cholesterol level49. Macrophage
cholesterol biosynthesis and PON2 expression was nega-
tively correlated in Delta6-Desaturase knockout mice50.
Despite decreased cholesterol in ID8hPON2 cells, plasma
cholesterol was not significantly changed in mice receiv-
ing ID8hPON2 compared to ID8EV. In the current study,
neither caveolin-1 nor IGF-1R protein levels were chan-
ged (Fig. 6c), but the interaction was impaired (Fig. 6c). It
has been reported that depleting cholesterol in cells or
sequestering cholesterol from the membrane causes a
shift in raft and caveolar proteins and hormonal receptors
to other parts of the plasma membrane46. It has been
reported that cavolin-1 regulates the IGF-1R signaling in
H9C2 cells, rat cardio myoblasts and adipose tissue51.
Hormonal receptor-caveolin-1 interaction is cell specific.
For instance, The interaction of insulin receptor–cavolin-
1 influences IRS-1 in COS-7 cells but not adipose cells,
upon insulin binding52
Why is PON2 a good target for ovarian cancer therapy?
Clinical studies suggest a role for IGF-1 in ovarian
cancer etiology. For example: (1) a prospective study from
Lukanova et al.53 demonstrated that there was a positive
correlation between circulating IGF-I levels and the risk
of developing ovarian cancer. (2) Brokaw et al.54 reported
that women with high IGF-I mRNA and IGF-1 peptide
levels were at a greater risk for disease progression
compared to those with low levels, suggesting that IGF-I
is involved in ovarian cancer progression. (3) Altered
expression of IGF axis member genes was associated with
poor prognosis in epithelial ovarian cancer55. Several
small molecule tyrosine kinase inhibitors against IGF-1R
inhibited tumor growth in vivo model56. However,
because of the high degree of homology between IGF-1R
and insulin receptor (IR), most specific IGF-1R tyrosine
kinase inhibitors (TKIs) have inhibitory effects on the
IR57. For instance, OSI-906, has a half maximal inhibitory
concentration (IC50) of 0.018 µmol L
−1 and 0.054 µmol
L−1 against IGF-1R and IR, respectively57. It is docu-
mented that impaired IR signaling induces hyperglycemia
and toxicity58. Hence, instead of directly targeting IGF-1/
IGF-1R, which has adverse effect on glucose hemostasis,
activating PON2 would be a fruitful alternative strategy
for treating ovarian cancer. Altogether, our study
demonstrated for the first time that PON2 inhibits ovar-
ian tumor growth.
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